Coexistence of MSI with KRAS mutation is associated with worse prognosis in colorectal cancer

about

Verification of the methodology for evaluating tumor-infiltrating lymphocytes in colorectal cancer.

P2860

Q55385663-2B285C47-810E-4C4E-BAA5-B2EEC5AF6EB6

P2860

Coexistence of MSI with KRAS mutation is associated with worse prognosis in colorectal cancer

Item

http://www.wikidata.org/entity/Q37608405

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on December 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Coexistence of MSI with KRAS m ...... prognosis in colorectal cancer

@en

Coexistence of MSI with KRAS m ...... rognosis in colorectal cancer.

@nl

type

Item

label

Coexistence of MSI with KRAS m ...... prognosis in colorectal cancer

@en

Coexistence of MSI with KRAS m ...... rognosis in colorectal cancer.

@nl

prefLabel

Coexistence of MSI with KRAS m ...... prognosis in colorectal cancer

@en

Coexistence of MSI with KRAS m ...... rognosis in colorectal cancer.

@nl

P1476

Coexistence of MSI with KRAS m ...... prognosis in colorectal cancer

@en

P2093

Bao-Rui Liu

http://www.w3.org/2001/XMLSchema#string

Jing Hu

http://www.w3.org/2001/XMLSchema#string

Jiong Shi

http://www.w3.org/2001/XMLSchema#string

Lei Cheng

http://www.w3.org/2001/XMLSchema#string

Li Li

http://www.w3.org/2001/XMLSchema#string

Li Xie

http://www.w3.org/2001/XMLSchema#string

Mi Yang

http://www.w3.org/2001/XMLSchema#string

Wen-Yue Yan

http://www.w3.org/2001/XMLSchema#string

Xiao-Ping Qian

http://www.w3.org/2001/XMLSchema#string

P2860

Microsatellite instability in colorectal cancer

Global cancer statistics, 2012

Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.

Microsatellite instability among individuals of Hispanic origin with colorectal cancer

KRAS, BRAF and PIK3CA mutations and the loss of PTEN expression in Chinese patients with colorectal cancer

BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients.

Kras gene mutation and RASSF1A, FHIT and MGMT gene promoter hypermethylation: indicators of tumor staging and metastasis in adenocarcinomatous sporadic colorectal cancer in Indian population

Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes

P304

e5649

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/MD.0000000000005649

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27977612

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

5268058

http://www.w3.org/2001/XMLSchema#string

Coexistence of MSI with KRAS mutation is associated with worse prognosis in colorectal cancer

about

P2860

P2860

Coexistence of MSI with KRAS mutation is associated with worse prognosis in colorectal cancer

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P932